A Penn center studying public policy and communication.
Moderna has won FDA approval for its mRNA flu vaccine mFlusiva for adults 50–64 and accelerated approval for those 65 and older. The decision follows a contentious review earlier this year, a unanimous advisory panel recommendation in June and political disputes inside US health agencies over mRNA vaccines. Retail availability is expected in coming weeks.
Texas politics are shifting as districts face rising backlash over data centers. A four-point plan aims to curb Chinese tech, protect children, and cut tax exemptions, while opponents accuse leaders of courting big tech and dodging local concerns. Polls show broad cross‑party opposition to new centers, potentially altering the 2026 midterms and beyond.